The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >
Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >
Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >
Explore a diverse range of engaging video content, from fascinating experiments showcasing cutting-edge research to heartfelt customer testimonials.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >
Let’s change the NGS market together – our global presence and partners world-wide
View Detail >
Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Science is a collaborative process which works best when new knowledge is shared.
We contribute to this by presenting our research at scientific congresses and publishing our results in scientific journals.
Park U, Lee JH, Kim U, Jeon K, Kim Y, Kim H, Kang JI, Park MY, Park SH, Cha JS, Yoon GY. A humanized ACE2 mouse model recapitulating age‐and sex‐dependent immunopathogenesis of COVID‐19. Journal of Medical Virology. 2024 Sep;96(9):e29915.
10.1002/jmv.29915
Han JY, Gwack J, Kim TY, Park J. A Korean Family Presenting with Renal Cysts and Maturity-Onset Diabetes of the Young Caused by a Novel In-Frame Deletion of HNF1B. International Journal of Molecular Sciences. 2024 Sep 11;25(18):9823.
10.3390/ijms25189823
Rhim JW, Kim DK, Han JY, Park J. A sensorineural hearing loss harboring novel compound heterozygous variant in the TRIOBP gene: A Case report. Heliyon. 2024 Sep 4.
10.1016/j.heliyon.2024.e36717
Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.
10.4143/crt.2023.1324
Kim B, Kim Y, Cho JY, Lee KA. Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer. Annals of laboratory medicine. 2024 Mar 1;44(2):164-73.
10.3343/alm.2023.0187
